Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer
Authors:
- Marek CybulskiMCMarek Cybulski
- Bożena JaroszBJBożena Jarosz
- Andrzej NowakowskiANAndrzej Nowakowski
- Witold JeleniewiczWJWitold Jeleniewicz
- Przemysław SeroczyńskiPSPrzemysław Seroczyński
- Magdalena Mazurek-KociubowskaMMMagdalena Mazurek-Kociubowska
- 1 October 2012
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 127 (1) , 217-222
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Higher Education of Poland (N407 092 32/3452)
This publication has 29 references indexed in Scilit:
- Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer MetastasisClinical Cancer Research, 2011
- Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancerBreast Cancer Research and Treatment, 2010
- Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and CancerGenes & Cancer, 2010
- Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian CancerMolecular Cancer Therapeutics, 2010
- Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasisEndocrine-Related Cancer, 2010
- Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysHuman Pathology, 2010
- Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cellsJournal of Clinical Investigation, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Functional significance of VEGFR‐2 on ovarian cancer cellsInternational Journal of Cancer, 2008
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortiaGynecologic Oncology, 2008